Clinical pharmacology of azathioprine, 6-mercaptopurine and 6-thioguanine in the treatment of inflammatory bowel diseases;Therapie chronisch entzündlicher darmerkrankungen mit azathioprin, 6-mercaptopurin und 6-thioguanin

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 8, 2003, Pages 378-384

  Schwab, M ^a   Herrlinger, K ^b   Schaeffeler, E ^a   Stange, E F ^b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; TIOGUANINE;

ANEMIA; ARTHRALGIA; BONE MARROW SUPPRESSION; DIARRHEA; DRUG METABOLISM; ENTERITIS; ENZYME POLYMORPHISM; FEVER; HUMAN; INFECTION; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIVER HYPERPLASIA; LIVER TOXICITY; PANCREATITIS; PANCYTOPENIA; PNEUMONIA; REVIEW; THROMBOCYTOPENIA;

6-MERCAPTOPURINE; AZATHIOPRINE; BONE MARROW; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA, NON-HODGKIN; METHYLTRANSFERASES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOGUANINE;

EID: 0037458977     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37378     Document Type: Review

References (69)

1. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001; 15: 1101-1108
2. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998; 87: 108-111
3. Ansari A, Hassan C, Duley J et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 1743-1750
4. Bär U, Becker H, May B et al. Azathioprine pharmacokinetics in animal experiment and in patients with chronic liver diseases. Verh Dtsch Ges Inn Med 1973; 79: 943-946
5. Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (Or how pharmacogenomics can make old drugs brand new). Inflamm Bowel Dis 2001; 7: 190-191
6. Bebb JR, Aithal GP, Logan RP. Immunosuppression, IBD, and risk of lymphoma. Gut 2002; 51: 296
7. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001; 36: 71-76
8. Bouhnik Y, Lemann M, Mary JY et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-219
9. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002; 16: 389-398
10. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopunne S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioptine therapy. Gastroenterology 2000; 118: 1025-1030
11. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-1252
12. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-1085
13. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-406
14. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-646
15. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 79-85
16. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713
17. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991; 67: 2015-2019
18. Elion GB. The purine path to chemotherapy. Science 1989; 244: 41-47
19. Evans WE, Hon YY, Borngaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-2301
20. Fellermann K, Steffen M, Stein J et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 171-176
21. Fellermann K, Tanko Z, Herrlinger KR et al. Response of refractory colitis to intravenous or oral tacrolimus. Inflamm Bowel Dis 2002; 8: 317-324
22. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
23. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 1225-1232
24. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239
25. Herrlinger KR, Kreisel W, Schwab M et al. 6-thioguanine - efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; im Druck
26. Hildner K, Marker-Hermann E, Schlaak JF et al. Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells. Ann NY Acad Sci 1998; 859: 204-207
27. Kaskas BA, Louis E, Hindorf U et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-142
28. Kroeplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54: 265-271
29. Lennard L, Lilleyman JS, Van Loon J. Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-229
30. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-339
31. Lennard L. Clinical implications of thiopurine methyl-transferase - optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20: 527-531
32. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 143-146
33. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-1024
34. Lewis LD, Benin A, Szumlanski CL et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464-475
35. Lowry PW, Franklin CL, Weaver AL et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-664
36. Lowry PW, Franklin CL, Weaver AL et al. Measurement of thiopurine methyl-transferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-670
37. Lowry PW, Szumlanski CL, Weinshilboum RM, Sandborn WJ. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology 1999; 116: 1505-1506
38. Ludwig D, Stange EF German Imurek Study Group. Efficacy of azathioprine in the treatment of chronic active Crohn's disease: prospective one-year follow-up study. Z Gastroenterol 1999; 37: 1085-1091
39. McBride KL, Gilchrist GS, Smithson WA, Weinshilboum RM, Szumlanski CL. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency. J Pediatr Hematol Oncol 2000; 22: 441-445
40. McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 838-839
41. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98
42. Nink K, Schröder H. Ergänzende statistische Übersicht. Berlin: Springer-Verlag, In: Schwabe U, Paffrath D, Hrsg. Arzneiverordnungs-Report 2001. 2001: 846-930
43. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516
44. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-142
45. Persson PG, Karlen P, Bernell O et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994; 107: 1675-1679
46. Poordad F, Vasiliausless E, Abreu Met al. Nodular regenerative hyperplasia (NRH) of the liver associated with 6-thioguanine (6-TG) therapy in inflammatory bowel disease (IBD)(abstract #680). Hepatology 2002; 36: 333A
47. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz Bl. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649
48. Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13: 287-290
49. Sandborn WJ, Tremaine WJ, Wolf DC et al. North American Azathioprine Study Group. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology 1999; 117: 527-535
50. Sandborn W, Suthedand L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000545
51. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. G ut 2001; 48: 591-592
52. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40: 723-751
53. Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology 2001; 121: 498-499
54. Schwab M, Schaeffeler E, Marx C et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-436
55. Sebbag L, Boucher P, Davelu P et al. Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 2000; 69: 1524-1527
56. Shipkova M, Armstrong VW, Wieland E, Oellerich M. Differences in Nucleotide Hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem 2003; 49: im Druck
57. Stange EF, Modigliani R, Pena AS, Wood AJ, Feutren G. Smith PR The European Study Group. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology 1995; 109: 774-782
58. Stange EF, Riemann J, von Herbay A et al. Diagnosis and therapy of ulcerative colitis - results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 2001; 39: 19-20
59. Stange EF, Schreiber S, Foelsch U et al. Diagnostik und Therapie des Morbus Crohn - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Z Gastroenterol 2003; 41: 19-20
60. Stolk LC, Broxson EH, Sather H et al. Oral 6-thioguanine causes late-onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia (abstract T833). Gastroenterology 2002; 122 (Suppl);
61. Swann PF, Waters TR, Moulton DC et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-1111
62. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-459
63. Tidd DM, Paterson AR. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974; 34: 733-737
64. Tiede I, Fritz G, Wirtz S et al. 6-Thio-GTP vermittelte funktionelle Hemmung der GTPase Rac1: Identifikation eines molekularen Wirkungsmechanismus von Azathioprin bei chronisch entzündlichen Darmerkrankungen (Abstrakt PL 6). Z Gastroenterol 2002; 40: 603
65. Van Os EC, Zins BJ, Sandbom WJ et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996; 39: 63-68
66. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662
67. Wood TC, Johnson KL, Naylor S. Weinshilboum RM. Cefazolin Administration and 2-Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia. Drug Metab Dispos 2002; 30: 1123-1128
68. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614
69. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983; 34: 810-817